News & Thinkingyogesh2023-02-13T17:07:35+00:00

Stay up-to-date on our

Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and Outcomes

Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney Disease

Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™ with Primary Care Physicians

1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients

KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort

Renalytix Announces Two Data Presentations on KidneyIntelX™ at American Diabetes Association 82nd Scientific Sessions^®

Don’t miss our latest inspiring & original thinking.

Read Blogs

It’s not just analytics.
It’s Bioprognosis™.

Well Filtered™

Get access to the blog, webinars and podcasts with the ideas, perspectives and innovations that matter most in kidney health.

Renalytix is seeking FDA De Novo marketing authorization for KidneyIntelX. The test is not FDA approved nor cleared for any use at this time. KidneyIntelX yields a custom risk score that identifies which adult diabetic patients in early stages of chronic kidney disease are at low, intermediate or high risk for rapid progressive decline in kidney function within a period of up to five years. To report a product concern or suspected Adverse Event, please contact Renalytix Client Service at 1-888.203.2725.

© Renalytix.
Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data.